Review article · 2026 · Open access

Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms

Bushra Faryal, Zain Ul Abideen, Muhammad Irfan, Haseeb Ahmed, Fazliddin Sodiqovich Jalilov, Lola Abduraximova, Ghulam Abbas Ashraf

Biomolecules, 16(2), 325 · Published 19 February 2026 · DOI 10.3390/biom16020325

Open PDFView at the publisherCite this paper

In brief

“Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms” is a 2026 review article by Bushra Faryal and 6 co-authors, published in Biomolecules. OpenAlex counts 29 citations as of 19 November 2026. It is open access under a CC BY licence: the full text is free to read at Biomolecules.

Citations
29
Most cited in
2026 (27)
Field-weighted impact
13.45
References
182
Authors
7

Abstract

The onset of proteolysis targeting chimeras (PROTACs) has reshaped the entire context of targeted cancer therapy by offering a novel approach for the selective degradation of disease-causing proteins, overcoming the limitations of traditional occupancy-driven inhibition. This heterobifunctional technology recruits endogenous E3 ubiquitin ligases to mark proteins of interest (POI) for proteosomal degradation via the ubiquitin-proteasome system (UPS). Unlike conventional inhibitors, PROTACs function catalytically and can target previously “undruggable proteins”, such as transcription factors, scaffold proteins, and non-enzymatic regulators, offering potential to overcome acquired resistance and achieve potent efficacy at sub-stoichiometric doses. The review explores the latest innovations in PROTAC design, including E3 ligase selection, linker chemistry, and ligand optimization, while highlighting promising preclinical and clinical candidates against oncogenic drivers, anti-apoptotic factors (BCL-xL), and nuclear hormone receptors. Furthermore, we critically examine key translational challenges, such as pharmacokinetics, off-target effects, and resistance mechanisms, and discuss viable solutions, including dual E3 ligase engagement, novel modalities like AUTACs/ATTECs, LYTACs, and AI-driven design. As the field rapidly evolves from foundational to clinical application, PROTACs are redefining therapeutic possibilities, offering a robust, flexible, and scalable framework for the future of precision oncology.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Faryal, B., Abideen, Z. U., Irfan, M., Ahmed, H., Jalilov, F. S., Abduraximova, L., & Ashraf, G. A. (2026). Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms. Biomolecules, 16(2), 325. https://doi.org/10.3390/biom16020325

MLA 9

Faryal, Bushra, et al. “Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms.” Biomolecules, vol. 16, no. 2, 2026, p. 325. https://doi.org/10.3390/biom16020325.

Chicago

Faryal, Bushra, Zain Ul Abideen, Muhammad Irfan, Haseeb Ahmed, Fazliddin Sodiqovich Jalilov, Lola Abduraximova, and Ghulam Abbas Ashraf. 2026. “Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms.” Biomolecules 16 (2): 325. https://doi.org/10.3390/biom16020325.

Harvard

Faryal, B. et al. (2026) ‘Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms’, Biomolecules, 16(2), p. 325. doi:10.3390/biom16020325.

IEEE

B. Faryal et al., “Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms,” Biomolecules, vol. 16, no. 2, p. 325, 2026, doi: 10.3390/biom16020325.

BibTeX

@article{faryal2026targeted,
  title     = {{Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms}},
  author    = {Faryal, Bushra and Abideen, Zain Ul and Irfan, Muhammad and Ahmed, Haseeb and Jalilov, Fazliddin Sodiqovich and Abduraximova, Lola and Ashraf, Ghulam Abbas},
  journal   = {Biomolecules},
  year      = {2026},
  volume    = {16},
  number    = {2},
  pages     = {325},
  doi       = {10.3390/biom16020325},
  url       = {https://doi.org/10.3390/biom16020325}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors

  • PROTACs
  • targeted protein degradation
  • E3 ubiquitin ligase
  • ubiquitin-proteasome system
  • heterobifunctional molecules
  • undruggable proteins
  • Bcl-xL
  • nuclear receptors

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Faryal, B., Abideen, Z. U., Irfan, M., Ahmed, H., Jalilov, F. S., Abduraximova, L., & Ashraf, G. A. (2026). Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms. Biomolecules, 16(2), 325. https://doi.org/10.3390/biom16020325

How many times has this paper been cited?

29 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Biomolecules: sign in and open the PDF from this page.

Who wrote this paper?

Bushra Faryal, Zain Ul Abideen, Muhammad Irfan, Haseeb Ahmed, Fazliddin Sodiqovich Jalilov, Lola Abduraximova, Ghulam Abbas Ashraf.

What is the DOI of this paper?

10.3390/biom16020325, permanently at https://doi.org/10.3390/biom16020325. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.